Grifols (ADR)
Builds plasma-derived therapies, diagnostics, and biologic supplies around an integrated plasma network.
Something off on this page? Send us feedback.
Profile
Plasma collection supplies an integrated Biopharma chain of human-plasma therapies, while Diagnostic offers testing equipment and reagents. International operations include Bio Supplies, which offers non-therapeutic biological products and third-party plasma sales.
Plasma collection feeds an integrated Biopharma chain that fractionates human plasma and commercializes plasma-derived therapies. Diagnostic provides testing equipment and reagents, while Bio Supplies offers non-therapeutic biological products and third-party plasma sales.
Operations expanded from Spain through acquisitions in Europe and the United States, with activity also spanning Latin America, Africa, and Asia. Plasma Procurement, Biopharma, Diagnostic, Bio Supplies, and Others form the internal business structure; Plasma Procurement supplies Biopharma and produces no external revenue.
The model relies on plasma collection, complex fractionation and manufacturing, and regulated therapeutic and diagnostic markets.
Company facts
Key statistics
Year to date −16.8% · Average volume (30d) 590.8K
Analysts
No analyst consensus on record.
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Jul 28, 2026Q2 FY26 | $0.27 | $0.25 | −7.0% | $2.17B | $2.13B | −1.5% | +1.87% |
| May 7, 2026Q1 FY26 | $0.16 | $0.17 | +7.3% | $2.03B | $2.00B | −1.4% | +0.50% |
| Feb 26, 2026Q4 FY25 | $0.29 | $0.29 | −0.3% | $2.34B | $2.34B | −0.2% | +1.56% |
| Nov 4, 2025Q3 FY25 | $0.24 | $0.22 | −9.6% | $2.15B | $2.18B | +1.5% | −6.40% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $2.07B | $2.19B | $2.16B | $2.27B | $2.00B | $2.17B | |
| Gross profit | $816.4M | $861.8M | $870.8M | $788.4M | $730.2M | $815.7M | |
| Operating income | $311.5M | $404.2M | $444.1M | $315.4M | $293.3M | $381.2M | |
| Net income | $69.2M | $135.6M | $147.1M | $112.8M | $86.0M | $178.4M | |
| Diluted EPS | $0.10 | $0.20 | $0.22 | $0.16 | $0.13 | $0.27 | |
| Gross margin | 39.5% | 39.3% | 40.3% | 34.7% | 36.5% | 37.6% | |
| Operating margin | 15.1% | 18.4% | 20.5% | 13.9% | 14.6% | 17.6% |
Fiscal years (4-quarter sums)FY19 $5.91B · FY20 $6.74B · FY23 $7.62B · FY24 $8.36B · FY25 $8.70B
Revenue by product · FY25
Revenue by geography · FY25
Balance sheet, Jun 30, 2026Cash & short-term investments $612.9M · Total debt $9.87B · Total assets $23.28B · Shareholders' equity $6.43B
Dividends
Last cut to $0.1058 from $0.1758 in Jul 2026. To collect a payout, hold shares through the close before the ex-date.
History
| Ex-date | Record | Paid | Amount | Note |
|---|---|---|---|---|
| Jul 2, 2026 | Jul 2 | Jul 9 | $0.1058 | cut from $0.1758 |
| Aug 12, 2025 | Aug 12 | Aug 20 | $0.1758 |
Ownership
Shares outstanding 845.97M · Float 834.63M · 98.7% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Brandes Investment Partners, LP | 37.82M | 4.47% | 13F | Aug 14, 2026 |
| Capital World Investors | 22.91M | 2.71% | 13F | Aug 12, 2026 |
| Permian Investment Partners, LP | 19.74M | 2.33% | 13F | Aug 14, 2026 |
| Black Creek Investment Management Inc. | 7.68M | 0.91% | 13F | Aug 12, 2026 |
| Bank of America Corp /DE/ | 6.55M | 0.77% | 13F | Aug 14, 2026 |
Insider tradesForm 4
Nothing filed in the last 12 months.
View detailsPeers
- Takeda (ADR)
Plasma-derived immunoglobulin and alpha-1 therapy overlap
- argenx (ADR)
Non-plasma CIDP treatment alternative to subcutaneous immunoglobulin
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Grifols (ADR) | $7.69 | 0.00% | $6.51B | 9.9 | — | 0.9 | −4.2% |
| Takeda (ADR) | $18.49 | +2.53% | $57.37B | 51.0 | 53.7 | 2.0 | +5.8% |
| argenx (ADR) | $1,023.21 | −0.02% | $63.63B | 37.3 | — | 12.4 | — |
| Median | 44.2 | 53.7 | 7.2 | +5.8% |